Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 Apr;17(4):702-703.
doi: 10.1002/alz.12235. Epub 2020 Nov 1.

Open Peer Commentary to "Failure to demonstrate efficacy of aducanumab: An analysis of the EMERGE and ENGAGE Trials as reported by Biogen December 2019"

Marwan Noel Sabbagh  1 , Jeffrey Cummings  1   2
Affiliations
Comment

Open Peer Commentary to "Failure to demonstrate efficacy of aducanumab: An analysis of the EMERGE and ENGAGE Trials as reported by Biogen December 2019"

Marwan Noel Sabbagh et al. Alzheimers Dement. 2021 Apr.
No abstract available

PubMed Disclaimer

Comment on

References

    1. Knopman DS, Jones DT, Grecius MD. Failure to demonstrate efficacy of aducanumab: an analysis of EMERGE and ENGAGE trials reported by Biogen, December 2019. Alzheimer's Dement. 2021;17:696‐701. - PubMed
    1. Linse S, Scheidt T, Bernfur K, et al. Kinetic fingerprints differentiate the mechanisms of action of anti‐Aβ antibodies. Nat Struct Mol Biol. 2020. 10.1038/s41594-020-0505-6. Online ahead of print. PMID: 32989305. - DOI - PubMed
    1. Budd HS, von Hehn C, Tian Y, et al. CTAD. EMERGE and ENGAGE Topline Results: Two Phase 3 Studies to Evaluate Aducanumab in Patients with Early Alzheimer's Disease. San Diego. 2019. December 5.
    1. Sevigny J, Chiao P, Sandrock A. The antibody aducanumab reduces Aβ plaques in Alzheimer's disease. Nature. 2016;537:50‐56. - PubMed
    1. Salloway S, Sperling R, Fox NC, et al, for the Bapineuzumab 301 and 302 Clinical Trial Investigators** . Intravenous bapineuzumab in mild‐to‐moderate Alzheimer disease: phase 3 clinical trial results in apolipoprotein E ε4 carriers and non‐carriers. N Engl J Med. 2014;370:322‐333. - PubMed

Publication types

Substances